Subscribe to Newsletter
Manufacture Vaccines, Technology and Equipment

Go Forth and Find a Flu Vaccine

The year 2018 marks the centenary of a flu pandemic that killed around 50 million people worldwide. Since then, significant efforts have been made to fight the flu, but a universal flu vaccine still eludes us – and thousands continue to die every year. In late April, the Bill and Melinda Gates Foundation launched a $12 million Grand Challenge: “[to] identify novel, transformative concepts that will lead to development of universal influenza vaccines offering protection from morbidity and mortality caused by all subtypes of circulating and emerging (drifted and shifted) Influenza A subtype viruses and Influenza B lineage viruses for at least three to five years”.

The foundation is looking for “bold ideas” and “unconventional approaches” – not marginal improvements or precedential approaches, such as the use of biosimilars, monoclonal antibodies, or the development of new assays, adjuvants, and so on. Examples of what the foundation is looking for include:

  • Antigen-centric: discovering new antigens/targets through artificial intelligence or deep learning.
  • Host-centric: approaches that generate, enhance, or modify human immune protection, or that ensure longer term immune response.
  • Technology-centric: including novel vaccine concepts, targets and constructs inspired by new understanding about the nature of the influenza or immune response; and applications of new technologies for disease protection.
  • Enabling advances: including challenge models to quickly demonstrate safety and proof-of-concept for influenza vaccines.

The aim is to develop a vaccine that is ready to start clinical trials by 2021. Pilot funding will be offered in the region of $250,000 to $2 million. Upon the demonstration of proof-of-concept, projects will be invited to apply for a full award of up to $10 million. Applicants don’t need to have an industry partner, but such collaborations will be considered. Industry is also welcome to apply.

If you think you’re up to the challenge, bear in mind that the deadline for submissions is June 22, 2018: 
apply here

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine